Trial Evaluating Nutritional Fiber in Digestive Symptoms of Endometriosis (TEND)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Mechanistic Effects of a Multi-Fiber Prebiotic Dietary Supplement (LOAM) on the Gut and Vaginal Microbiome, Gastrointestinal Well-Being, and Quality-of-Life Parameters in Women With Endometriosis and Co-Existing Gastrointestinal Symptoms
This study is a double-blind, randomized, placebo-controlled study that evaluates the safety and tolerability of a fiber-based dietary supplement and the mechanistic and structure-function effects of that supplement on the gut and vaginal microbiome, gastrointestinal well-being, and quality-of-life parameters in 140 women with endometriosis and co-existing gastrointestinal symptoms over 12 weeks. The primary objective is to evaluate the safety and tolerability of the supplement, measured by the incidence and severity of gastrointestinal adverse events (AEs) and discontinuations. Secondary objectives include assessing the fibers impact on gastrointestinal symptoms and quality of life through the use of custom questionnaires built for the study population and evaluation of other endometriosis related parameters such as pelvic discomfort. Exploratory objectives focus on the exploration of the gut and vaginal microbiomes, their connection to endometriosis, and how they are impacted by the study product.
Studieoversigt
Status
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Bryce Jarman, PhD
- Telefonnummer: 323-325-1327
- E-mail: bryce@loamscience.com
Studiesteder
-
-
California
-
San Francisco, California, Forenede Stater, 94109
- Rekruttering
- Alethios
-
Kontakt:
- Zeenia Framroze
- Telefonnummer: (650) 206-8006
- E-mail: zeenia@alethios.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Confirmed diagnosis of endometriosis (by imaging, laparoscopy, or physician clinical assessment).
- Enriched gastrointestinal phenotype: self-reported gastrointestinal symptoms on at least 3 days per week for the preceding 3 months, including at least one of bloating, constipation, or abdominal discomfort
- Predominantly Bristol Stool Scale Type 1-3 (constipation-predominant), or self-reported bloating as a dominant symptom.
- Stable hormonal status: either no hormonal therapy, or stable hormonal therapy (combined oral contraceptive, progestin, or GnRH analogue) for at least 3 months with no planned change during the study.
- Estimated habitual dietary fiber intake below 25 g/day based
- Willingness to share menstrual cycle data.
- Willing to maintain stable diet, physical activity, and medication regimens throughout the study.
- Able to provide electronic informed consent and to comply with stool and vaginal self-sampling procedures.
- Ownership and consistent use of a home body-weight scale for the duration of the study, to support the standardized at-home morning weighing protocol.
Exclusion Criteria:
- Inflammatory bowel disease (Crohn's disease, ulcerative colitis), celiac disease, or other organic gastrointestinal disease.
- Severe irritable bowel syndrome (IBS) requiring active pharmacological management. Mild-to-moderate overlap is permitted as part of the enrichment strategy.
- Antibiotic use within 8 weeks prior to baseline or anticipated during the study.
- Probiotic, prebiotic, or fiber supplement use within 4 weeks prior to baseline (washout required).
- Major gastrointestinal surgery, excluding appendectomy or cholecystectomy more than 6 months prior, and excluding surgical intervention for endometriosis.
- Current pregnancy, breastfeeding, or plans to conceive during the study.
- Severe constipation requiring regular prescription laxatives.
- Significant renal, hepatic, cardiac, or endocrine disease.
- Active malignancy.
- Known allergy or intolerance to any LOAM fiber component.
- Significant dietary change or weight-loss intervention within the preceding 3 months.
- Use of medications known to significantly alter gut motility or the microbiome (for example, recent metformin initiation, regular opioid use, or chronic proton-pump inhibitor use), per investigator judgment.
- Any surgical intervention for endometriosis (including laparoscopy, laparotomy, or endometrioma excision) within the 6 months prior to screening, as post-surgical physiological changes may confound symptom and biomarker assessments.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Andet
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Fiber Supplement
Fiber supplement providing 20 grams/day of dietary fiber. Taken as a scoop of powder added to a drink twice daily. |
Dietary fiber blend containing six prebiotic fibers. |
|
Placebo komparator: Placebo Control
Placebo control. Taken as a scoop of powder added to a drink twice daily. |
Placebo control |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and severity of GI adverse events (AEs) and discontinuations.
Tidsramme: An adverse event questionnaire will be administered at baseline and at Week 4, Week 6, Week 8, and Week 12 of supplementation. Adverse events will also be collected ad hoc throughout the study period via a reporting form.
|
To evaluate the safety and tolerability of the fiber blend. |
An adverse event questionnaire will be administered at baseline and at Week 4, Week 6, Week 8, and Week 12 of supplementation. Adverse events will also be collected ad hoc throughout the study period via a reporting form.
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in a custom gut health questionnaire
Tidsramme: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
A custom gut health questionnaire using a 5-point Likert Scale (1-5) where 1 is no symptoms and 5 is the worst symptoms designed to evaluate GI symptoms relevant to endometriosis. |
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
DASS-21
Tidsramme: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Self-reported mental health tool to evaluate depression, anxiety, and stress that uses a 4-point Likert Scale (0-3) where 0 is not applicable and 3 is highly applicable. |
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Pelvic discomfort duration over 24 hours
Tidsramme: From baseline sample collection through the end of supplementation (Daily).
|
Evaluation of pelvic discomfort associated with endometriosis over the previous 24 hours using a 0-24 scale, where 0 is no hours of pelvic discomfort and 24 is pelvic discomfort for the entire duration of the last 24 hours. |
From baseline sample collection through the end of supplementation (Daily).
|
|
Pelvic discomfort severity
Tidsramme: From baseline sample collection through the end of supplementation (daily).
|
Pelvic discomfort severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort. |
From baseline sample collection through the end of supplementation (daily).
|
|
Body Weight
Tidsramme: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Performed at home using a scale |
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Gut Microbiome Composition
Tidsramme: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
Evaluation of the gut microbiome composition using shotgun metagenomic sequencing. |
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
|
Gut Microbiome Function
Tidsramme: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
Evaluation of the gut microbiome function using shotgun metagenomic sequencing. |
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
|
Vaginal Microbiome Composition
Tidsramme: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
Evaluation of the vaginal microbiome composition using shotgun metagenomic sequencing. |
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
|
Custom endometriosis quality of life survey
Tidsramme: From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
A custom survey designed to assess the impact of endometriosis on an individuals quality of life. Questions are scored using a 5-point Likert Scale (1-5) where 1 is no impact on quality of life and 5 is the highest level of impact. |
From baseline sample collection through the end of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Vaginal Microbiome Function
Tidsramme: Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
Evaluation of the vaginal microbiome function using shotgun metagenomic sequencing. |
Three separate samplings, one at baseline, one at six weeks, and one at 12 weeks.
|
|
Endometriosis-related Medication Use
Tidsramme: From enrollment through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Medication use assess by open-ended questionnaire. |
From enrollment through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Deep dyspareunia
Tidsramme: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Deep dyspareunia severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort. |
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Dysmenorrhea
Tidsramme: From baseline through the conclusion of supplementation (daily).
|
Dysmenorrhea severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort. |
From baseline through the conclusion of supplementation (daily).
|
|
Non-menstrual pelvic discomfort
Tidsramme: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Non-menstrual pelvic discomfort severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort. |
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Dyschezia
Tidsramme: From baseline through the conclusion of supplementation (daily).
|
Dyschezia severity assessed using a 10 point numerical rating scale (0-10) with zero being no discomfort and ten being the highest level of discomfort. |
From baseline through the conclusion of supplementation (daily).
|
|
Productivity Impairment
Tidsramme: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Measured using the Work Productivity and Activity Impairment Questionnaire, which includes open ended questions to assess hours missed as well as personal assessments of productivity using a 10 point numerical rating scale (0-10) with zero being no effect and ten being highly impacted. |
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
|
Bloating severity and abdominal girth
Tidsramme: From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Bloating severity assessed using a 10 point numerical rating scale (0-10) with zero being no bloating and ten being the highest level of bloating and abdominal girth measured by tape measure. |
From baseline through the conclusion of supplementation (Baseline, Week 4, Week 6, Week 8, and Week 12).
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Bryce Jarman, PhD, LOAM Science
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- LOA001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data is proprietary data.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .